



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
Main Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2021

---

**Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma**

van den Bent, Martin ; Eoli, Marica ; Sepulveda, Juan Manuel ; Smits, Marion ; Walenkamp, Annemiek ; Frenel, Jean-Sebastian ; Franceschi, Enrico ; Clement, Paul M ; Chinot, Olivier ; de Vos, Filip ; Whenham, Nicolas ; Sanghera, Paul ; Weller, Michael ; Dubbink, H J ; French, Pim ; Looman, Jim ; Dey, Jyotirmoy ; Krause, Scott ; Ansell, Pete ; Nuyens, Sarah ; Spruyt, Maarten ; Brillhante, Joana ; Coens, Corneel ; Gorlia, Thierry ; Golfopoulos, Vassilis

DOI: <https://doi.org/10.1093/neuonc/noaa115>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-206287>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) License.

Originally published at:

van den Bent, Martin; Eoli, Marica; Sepulveda, Juan Manuel; Smits, Marion; Walenkamp, Annemiek; Frenel, Jean-Sebastian; Franceschi, Enrico; Clement, Paul M; Chinot, Olivier; de Vos, Filip; Whenham, Nicolas; Sanghera, Paul; Weller, Michael; Dubbink, H J; French, Pim; Looman, Jim; Dey, Jyotirmoy; Krause, Scott; Ansell, Pete; Nuyens, Sarah; Spruyt, Maarten; Brillhante, Joana; Coens, Corneel; Gorlia, Thierry; Golfopoulos, Vassilis (2021). Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. *Neuro-Oncology*, 23(8):1415.

DOI: <https://doi.org/10.1093/neuonc/noaa115>

## INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

**Martin van den Bent, Marica Eoli, Juan Manuel Sepulveda, Marion Smits, Annemiek Walenkamp, Jean-Sebastian Frenel, Enrico Franceschi, Paul M. Clement, Olivier Chinot, Filip de Vos, Nicolas Whenham, Paul Sanghera, Michael Weller, H. J. Dubbink, Pim French, Jim Looman, Jyotirmoy Dey, Scott Krause, Pete Ansell, Sarah Nuyens, Maarten Spruyt, Joana Brilhante, Corneel Coens, Thierry Gorlia, and Vassilis Golinopoulos**

Corrigendum to Bent et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. *Neuro Oncol* (doi: 10.1093/neuonc/noz222) first published online November 20, 2019.

In table 2, the rows in the hematology and investigation sections were misplaced one line. This has been corrected.